JP2018203673A - Sebum secretion promoter - Google Patents
Sebum secretion promoter Download PDFInfo
- Publication number
- JP2018203673A JP2018203673A JP2017111634A JP2017111634A JP2018203673A JP 2018203673 A JP2018203673 A JP 2018203673A JP 2017111634 A JP2017111634 A JP 2017111634A JP 2017111634 A JP2017111634 A JP 2017111634A JP 2018203673 A JP2018203673 A JP 2018203673A
- Authority
- JP
- Japan
- Prior art keywords
- sebum secretion
- sebum
- skin
- oil
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002374 sebum Anatomy 0.000 title claims abstract description 103
- 230000028327 secretion Effects 0.000 title claims abstract description 86
- 229960000520 diphenhydramine Drugs 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 15
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 abstract description 30
- 210000003491 skin Anatomy 0.000 description 31
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 26
- 230000001737 promoting effect Effects 0.000 description 26
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 18
- 239000002628 heparin derivative Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- -1 diphenyl disulfonate Chemical class 0.000 description 15
- 210000001732 sebaceous gland Anatomy 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000006071 cream Substances 0.000 description 13
- 229920001296 polysiloxane Polymers 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 210000004207 dermis Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229940114124 ferulic acid Drugs 0.000 description 5
- 235000001785 ferulic acid Nutrition 0.000 description 5
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QVZGAIWUSYVGBJ-UHFFFAOYSA-N Cycloartenyl ferulate Natural products CCC12CCC3(C)C(C(C)CCC=C(C)C)CCC3(C)C1CCC(C1(C)C)C2CCC1OC(=O)C=CC1=CC=C(O)C(OC)=C1 QVZGAIWUSYVGBJ-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 208000001126 Keratosis Diseases 0.000 description 3
- 241000699673 Mesocricetus auratus Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940099373 sudan iii Drugs 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- JBSUVXVGZSMGDJ-YVMHCORFSA-N Oryzanol C Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC(=C)C(C)C)(C)C)=C1 JBSUVXVGZSMGDJ-YVMHCORFSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NSSALFVIQPAIQK-FPLPWBNLSA-N (Z)-2-Nonen-1-ol Chemical compound CCCCCC\C=C/CO NSSALFVIQPAIQK-FPLPWBNLSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- UYZQWKKNVBJVOF-UHFFFAOYSA-N 1-decoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCC UYZQWKKNVBJVOF-UHFFFAOYSA-N 0.000 description 1
- JPPRXACMNPYJNK-UHFFFAOYSA-N 1-docosoxydocosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCCCCCC JPPRXACMNPYJNK-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- UQOXSYQRUXKNQH-UHFFFAOYSA-N 1-hexadecoxyhexadecane;phosphoric acid Chemical compound OP(O)(O)=O.CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC UQOXSYQRUXKNQH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JWKSQNWLEIABLH-UHFFFAOYSA-N 1-octan-2-yloxydodecane Chemical compound CCCCCCCCCCCCOC(C)CCCCCC JWKSQNWLEIABLH-UHFFFAOYSA-N 0.000 description 1
- GQQNRZHWHWHOLI-UHFFFAOYSA-N 11-(2-decyltetradecoxymethyl)tricosane Chemical compound CCCCCCCCCCCCC(CCCCCCCCCC)COCC(CCCCCCCCCC)CCCCCCCCCCCC GQQNRZHWHWHOLI-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QKYLWBPOYURPBZ-UHFFFAOYSA-N 2-butyl-6-methoxyphenol;5-phenylnonan-5-ol Chemical compound CCCCC1=CC=CC(OC)=C1O.CCCCC(O)(CCCC)C1=CC=CC=C1 QKYLWBPOYURPBZ-UHFFFAOYSA-N 0.000 description 1
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 1
- IKVCSHRLYCDSFD-UHFFFAOYSA-N 2-hexadecanoyloxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCC IKVCSHRLYCDSFD-UHFFFAOYSA-N 0.000 description 1
- BXCRLBBIZJSWNS-UHFFFAOYSA-N 2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCO BXCRLBBIZJSWNS-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- BHVJSLPLFOAMEV-UHIFYLTQSA-M 20-Epibryonolic acid Natural products C([C@H]1[C@]2(C)CC3)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@]2(C)C1=C3[C@@]2(C)CC[C@H](O)C(C)(C)[C@@H]2CC1 BHVJSLPLFOAMEV-UHIFYLTQSA-M 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- BHVJSLPLFOAMEV-UHFFFAOYSA-N Bryonolic acid Natural products C1CC2(C)C3CC(C)(C(O)=O)CCC3(C)CCC2(C)C2=C1C1(C)CCC(O)C(C)(C)C1CC2 BHVJSLPLFOAMEV-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010014190 Eczema asteatotic Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- VNQABZCSYCTZMS-UHFFFAOYSA-N Orthoform Chemical compound COC(=O)C1=CC=C(O)C(N)=C1 VNQABZCSYCTZMS-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 210000000474 heel Anatomy 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000000453 juniperus communis l. leaf oil Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 229950006098 orthocaine Drugs 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、皮脂の分泌を促進できる皮脂分泌促進剤に関する。 The present invention relates to a sebum secretion promoter that can promote sebum secretion.
皮脂は、皮膚に柔軟性、弾力性、保湿性等を与えたり、紫外線や細菌等から皮膚を保護したりする作用があり、正常な皮膚状態を維持する上で重要な役割を果たしている。皮脂は、皮脂腺によって分泌されるが、年齢、体質、季節、ライフスタイル、薬物投与等の要因によってその分泌量が低下することがある。皮脂の分泌量の低下は、皮膚の柔軟性、弾力性、保湿性、皮膚の抵抗力等を低下させ、皮膚バリア機能の低下要因になっており、更には皮脂欠乏症、皮脂欠乏性湿疹、乾皮症、アトピー性皮膚炎、乾燥肌、ひび、あかぎれ等の皮膚症状や皮膚疾患の要因にもなっている。 Sebum plays an important role in maintaining a normal skin state because it has effects of imparting flexibility, elasticity, moisture retention and the like to the skin and protecting the skin from ultraviolet rays and bacteria. Sebum is secreted by the sebaceous glands, but the amount of secretion may decrease depending on factors such as age, constitution, season, lifestyle, and drug administration. Decrease in the amount of sebum secretion reduces skin flexibility, elasticity, moisture retention, skin resistance, etc., and is a factor that reduces skin barrier function. Furthermore, sebum deficiency, sebum deficiency eczema, dryness It is also a factor of skin symptoms and skin diseases such as dermatosis, atopic dermatitis, dry skin, cracks, and bruises.
従来、皮脂の分泌量の低下に対する対処策として、皮脂の構成成分であるトリグリセリド、ワックスエステル、スクアレン、遊離脂肪酸等の油分を含む外用組成物を用いて皮膚に油分を補給する方法が知られている。しかしながら、このような方法では、皮脂の分泌量の低下に対する対処療法にしかならず、その効果は限定的であり、根本的な解決策とはならないという欠点がある。 Conventionally, as a countermeasure against a decrease in sebum secretion, a method of replenishing the skin with an external composition containing oils such as triglycerides, wax esters, squalene, free fatty acids and the like, which are constituents of sebum, is known. Yes. However, such a method has a drawback that it is only a coping treatment for a decrease in the secretion amount of sebum, its effect is limited, and it is not a fundamental solution.
一方、皮脂の分泌量の低下に対する対処策として、皮脂の分泌を促進できる成分を使用して、皮脂の分泌量自体を増加させる方法も知られている。このような方法では、皮脂腺を賦活化させるため、皮脂の分泌量が低下した皮膚を効果的に改善できることが期待される。 On the other hand, as a countermeasure against a decrease in the sebum secretion amount, a method of increasing the sebum secretion amount itself by using a component capable of promoting sebum secretion is also known. In such a method, since the sebaceous glands are activated, it is expected that the skin in which the sebum secretion amount is reduced can be effectively improved.
従来、皮脂の分泌を促進上させる成分について種々報告されている。例えば、γ−オリザノールには、皮脂の分泌を促進作用があることが知られている。また、ビャクシ抽出物、ブリオノール酸、及びマルトオリゴ糖には、皮脂の分泌を促進作用があり、皮脂分泌促進剤に使用できることが報告されている（特許文献１〜３参照）。しかしながら、製剤処方の多様化、皮脂分泌促進作用の更なる向上等に対応するために、皮脂の分泌を促進させる新たな製剤技術の開発が望まれている。 Conventionally, various components that promote the secretion of sebum have been reported. For example, γ-oryzanol is known to have an action of promoting sebum secretion. In addition, it has been reported that juniper extract, bryonolic acid, and maltooligosaccharide have an action of promoting sebum secretion and can be used as a sebum secretion promoter (see Patent Documents 1 to 3). However, in order to cope with diversification of pharmaceutical formulations and further improvement of sebum secretion promoting action, development of a new pharmaceutical technology that promotes sebum secretion is desired.
本発明は、皮脂の分泌を促進させる皮脂分泌促進剤を提供することを目的とする。 An object of this invention is to provide the sebum secretion promoter which promotes the secretion of sebum.
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、ジフェンヒドラミン及び／又はその塩には、γ―オリザノールを凌ぐ皮脂分泌作用があり、皮脂分泌促進剤に使用可能であることを見出した。本発明は、かかる知見に基づいて更に検討を重ねることにより完成したものである。 As a result of diligent studies to solve the above-mentioned problems, the present inventor has found that diphenhydramine and / or a salt thereof has a sebum secretion action exceeding γ-oryzanol and can be used as a sebum secretion promoter. It was. The present invention has been completed by further studies based on such knowledge.
即ち、本発明は、以下に掲げる態様の発明を提供する。
項１． ジフェンヒドラミン及び／又はその塩を含有する、皮脂分泌促進剤。
項２． 皮膚外用剤である、項１に記載の皮脂分泌促進剤。
That is, this invention provides the invention of the aspect hung up below.
Item 1. A sebum secretion promoter containing diphenhydramine and / or a salt thereof.
Item 2. Item 2. The sebum secretion promoter according to Item 1, which is an external preparation for skin.
本発明の皮脂分泌促進剤によれば、皮脂の分泌を効果的に促進できるので、正常な皮膚状態に改善又は維持することが可能になっており、例えば、皮脂の分泌量の低下が要因の一つになっている皮膚疾患や皮膚症状の予防又は治療に有効である。 According to the sebum secretion-promoting agent of the present invention, it is possible to effectively promote the secretion of sebum, so that it is possible to improve or maintain a normal skin state. For example, a decrease in the amount of sebum secretion is a factor. It is effective in preventing or treating skin diseases and skin symptoms.
本発明の皮脂分泌促進剤は、ジフェンヒドラミン及び／又はその塩を含有することを特徴とする。以下、本発明の皮脂分泌促進剤について詳述する。 The sebum secretion promoter of the present invention is characterized by containing diphenhydramine and / or a salt thereof. Hereinafter, the sebum secretion promoter of the present invention will be described in detail.
ジフェンヒドラミン及び／又はその塩
ジフェンヒドラミン及び／又はその塩には、γ―オリザノールよりも高い皮脂分泌促進作用があり、本発明の皮脂分泌促進剤では、ジフェンヒドラミン及び／又はその塩を有効成分として含有する。
Diphenhydramine and / or salt thereof Diphenhydramine and / or salt thereof has a sebum secretion promoting action higher than that of γ-oryzanol, and the sebum secretion promoter of the present invention contains diphenhydramine and / or a salt thereof as an active ingredient.
ジフェンヒドラミンは、抗ヒスタミン作用があることが知られている公知の薬剤である。 Diphenhydramine is a known drug known to have an antihistamine action.
ジフェンヒドラミンの塩としては、薬学的に許容されるものである限り特に制限されないが、具体的には、塩酸塩、クエン酸塩、コハク酸塩、酒石酸塩、フマル酸塩、マレイン酸塩、サリチル酸塩、ジフェニルジスルホン酸塩、タンニン酸塩、ラウリル硫酸塩、硫酸塩等の酸付加塩が挙げられる。これらの塩は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 The salt of diphenhydramine is not particularly limited as long as it is pharmaceutically acceptable. Specifically, hydrochloride, citrate, succinate, tartrate, fumarate, maleate, salicylate And acid addition salts such as diphenyl disulfonate, tannate, lauryl sulfate, and sulfate. These salts may be used individually by 1 type, and may be used in combination of 2 or more type.
本発明の皮脂分泌促進剤は、ジフェンヒドラミン及びその塩の中から、１種を選択して使用してもよく、２種以上を組み合わせて使用してもよい。 The sebum secretion promoter of the present invention may be used by selecting one from diphenhydramine and a salt thereof, or may be used in combination of two or more.
ジフェンヒドラミン及びその塩の中でも、皮脂分泌促進作用をより一層効果的に向上させるという観点から、好ましくはジフェンヒドラミン、塩酸ジフェンヒドラミンが挙げられる。 Among the diphenhydramines and salts thereof, diphenhydramine and diphenhydramine hydrochloride are preferable from the viewpoint of further effectively improving the sebum secretion promoting action.
本発明の皮脂分泌促進剤におけるジフェンヒドラミン及び／又はその塩の含有量については、製剤形態等に応じて適宜設定すればよいが、例えば、例えば、０．０１〜５重量％が挙げられる。皮脂分泌促進作用をより一層効果的に向上させるという観点から、ジフェンヒドラミン及び／又はその塩の含有量として、好ましくは０．１〜３重量％、更に好ましくは０．１〜２重量％が挙げられる。 What is necessary is just to set suitably according to a formulation form etc. about content of diphenhydramine and / or its salt in the sebum secretion promoter of this invention, For example, 0.01-5 weight% is mentioned, for example. From the viewpoint of more effectively improving the sebum secretion promoting action, the content of diphenhydramine and / or a salt thereof is preferably 0.1 to 3% by weight, more preferably 0.1 to 2% by weight. .
ヘパリン類似物質
本発明の皮脂分泌促進剤は、ジフェンヒドラミン及び／又はその塩と共に、ヘパリン類似物質を含有してもよい。本発明者によってヘパリン類似物質にも皮脂分泌促進作用があることが見出されている。ジフェンヒドラミン及び／又はその塩とヘパリン類似物質とを併用することによって、相乗的に皮脂分泌促進作用を向上させることができる。
Heparin analog The sebum secretion promoter of the present invention may contain a heparin analog together with diphenhydramine and / or a salt thereof. It has been found by the present inventor that a heparin-like substance also has a sebum secretion promoting action. The combined use of diphenhydramine and / or a salt thereof and a heparin-like substance can synergistically improve the sebum secretion promoting action.
ヘパリン類似物質とは、コンドロイチン多硫酸等の多硫酸化ムコ多糖であり、保湿作用、抗炎症作用、血行促進作用等を有することが知られている公知の薬剤である。 Heparin-like substances are polysulfated mucopolysaccharides such as chondroitin polysulfate and are known drugs known to have moisturizing action, anti-inflammatory action, blood circulation promoting action, and the like.
本発明で使用されるヘパリン類似物質の由来については、特に制限されないが、例えば、ムコ多糖類を多硫酸化することにより得られたもの、食用獣の組織（例えば、ウシやブタ等の気管軟骨を含む肺臓）から抽出したもの等が挙げられる。本発明の皮脂分泌促進剤では、ヘパリン類似物質として、日本薬局方外医薬品規格に収戴されているヘパリン類似物質が好適に使用される。 The origin of the heparin-like substance used in the present invention is not particularly limited. For example, it is obtained by polysulfating mucopolysaccharides, tissues of edible animals (for example, tracheal cartilage such as cattle and pigs) And the like extracted from the lung including In the sebum secretion-promoting agent of the present invention, a heparin-like substance included in the Japanese Pharmacopoeia pharmaceutical standards is preferably used as the heparin-like substance.
本発明の皮脂分泌促進剤においてヘパリン類似物質を含有させる場合、その含有量については、特に制限されないが、例えば、０．０５〜１重量％が挙げられる。皮脂の分泌をより一層効果的に促進させるという観点から、ヘパリン類似物質の含有量として、好ましくは０．０５〜０．３重量％、更に好ましくは０．１〜０．３重量％が挙げられる。 In the case of containing a heparin-like substance in the sebum secretion-promoting agent of the present invention, the content is not particularly limited, and examples thereof include 0.05 to 1% by weight. From the viewpoint of more effectively promoting the secretion of sebum, the content of the heparin-like substance is preferably 0.05 to 0.3% by weight, more preferably 0.1 to 0.3% by weight. .
本発明の皮脂分泌促進剤においてヘパリン類似物質を含有させる場合、ジフェンヒドラミン及び／又はその塩に対するヘパリン類似物質の比率については、前述する各成分の含有量に応じて定まるが、例えば、ジフェンヒドラミン及び／又はその塩１００重量部当たり、ヘパリン類似物質が１〜１００００重量部が挙げられる。皮脂分泌促進作用をより一層効果的に向上させるという観点から、ジフェンヒドラミン及び／又はその塩１００重量部当たり、ヘパリン類似物質が、好ましくは１０〜３００重量部、更に好ましくは４０〜８０重量部が挙げられる。 In the case of containing a heparin-like substance in the sebum secretion promoter of the present invention, the ratio of the heparin-like substance to diphenhydramine and / or a salt thereof is determined according to the content of each component described above. For example, diphenhydramine and / or The heparin analog is 1 to 10,000 parts by weight per 100 parts by weight of the salt. From the viewpoint of improving the sebum secretion promoting effect more effectively, heparin-like substance is preferably 10 to 300 parts by weight, more preferably 40 to 80 parts by weight per 100 parts by weight of diphenhydramine and / or its salt. It is done.
γ−オリザノール
本発明の皮脂分泌促進剤は、更にγ−オリザノールを含有してもよい。γ−オリザノールは、皮脂分泌促進作用があることが知られており、ジフェンヒドラミン及び／又はその塩とγ−オリザノールを併用することによって、格段に優れた皮脂分泌促進作用を発揮させることが可能になる。特に、ジフェンヒドラミン及び／又はその塩と、ヘパリン類似物質と、γ−オリザノールとを組み合わせた場合には、これらの成分の相乗作用によって皮脂分泌促進作用を飛躍的に向上させることができる。
γ-Oryzanol The sebum secretion promoter of the present invention may further contain γ-oryzanol. It is known that γ-oryzanol has a sebum secretion promoting action, and by using diphenhydramine and / or a salt thereof and γ-oryzanol together, it becomes possible to exert a particularly excellent sebum secretion promoting action. . In particular, when diphenhydramine and / or a salt thereof, a heparin-like substance, and γ-oryzanol are combined, the sebum secretion promoting action can be dramatically improved by the synergistic action of these components.
γ−オリザノールとは、フェルラ酸とトリテルペンアルコールとのエステル、又はフェルラ酸とステロールとのエステルである。 γ-Oryzanol is an ester of ferulic acid and triterpene alcohol or an ester of ferulic acid and sterol.
本発明の皮脂分泌促進剤において、γ−オリザノールとして、フェルラ酸とトリテルペンアルコールとのエステル又はフェルラ酸とステロールとのエステルのいずれか一方を単独で使用してもよく、またこれらを組み合わせて使用してもよい。本発明で使用されるγ−オリザノールの好適な例として、フェルラ酸シクロアルテニル（Ｃ40Ｈ58Ｏ4）を含むもの、更に好ましくはフェルラ酸シクロアルテニルを９５重量％以上含むもの、特に好ましくはフェルラ酸シクロアルテニル９８重量％以上含むものが挙げられる。 In the sebum secretion promoter of the present invention, as γ-oryzanol, either an ester of ferulic acid and triterpene alcohol or an ester of ferulic acid and sterol may be used alone or in combination. May be. Preferred examples of γ-oryzanol used in the present invention include those containing cycloartenyl ferulate (C 40 H 58 O 4 ), more preferably those containing 95 wt% or more of cycloartenyl ferulate, particularly preferably Include those containing 98% by weight or more of cycloartenyl ferulate.
γ−オリザノールのＣＡＳ登録番号は、「１１０４２−６４−１」で表される。本発明で使用されるγ−オリザノールには、オリザノールＡ（ＣＡＳ登録番号［２１２３８−３３−５］）及びオリザノールＣ（ＣＡＳ登録番号［４６９−３６−３］）等が含まれ得る。 The CAS registration number of γ-oryzanol is represented by “11042-64-1”. The γ-oryzanol used in the present invention may include oryzanol A (CAS registration number [21238-33-5]) and oryzanol C (CAS registration number [469-36-3]).
本発明で使用されるγ−オリザノールについては、その原料、製造方法、精製方法等は特に限定されず、例えば、米糠等から自ら単離及び精製したもの等が挙げられる。 About the (gamma)-oryzanol used by this invention, the raw material, a manufacturing method, a refinement | purification method, etc. are not specifically limited, For example, what isolated and refine | purified itself from the rice bran etc. is mentioned.
本発明の皮脂分泌促進剤においてγ−オリザノールを含有させる場合、その含有量については、特に制限されないが、例えば、０．０５重量％以上が挙げられる。皮脂分泌促進作用をより一層効果的に向上させるという観点から、γ−オリザノールの含有量として、好ましくは０．０５〜２重量％、更に好ましくは０．１〜１重量％、特に好ましくは０．５〜１重量％が挙げられる。 When γ-oryzanol is contained in the sebum secretion promoter of the present invention, the content thereof is not particularly limited, but examples include 0.05% by weight or more. From the viewpoint of more effectively improving the sebum secretion promoting action, the content of γ-oryzanol is preferably 0.05 to 2% by weight, more preferably 0.1 to 1% by weight, and particularly preferably 0. 5 to 1% by weight is mentioned.
本発明の皮脂分泌促進剤においてγ−オリザノールを含有させる場合、ジフェンヒドラミン及び／又はその塩に対するγ−オリザノールの比率については、前述する各成分の含有量に応じて定まるが、例えば、ジフェンヒドラミン及び／又はその塩１００重量部当たり、γ−オリザノールが１〜２００００重量部が挙げられる。皮脂分泌促進作用をより一層効果的に向上させるという観点から、ジフェンヒドラミン及び／又はその塩１００重量部当たり、γ−オリザノールが、好ましくは５０〜４００重量部、更に好ましくは１５０〜２５０重量部が挙げられる。 When γ-oryzanol is contained in the sebum secretion promoter of the present invention, the ratio of γ-oryzanol to diphenhydramine and / or a salt thereof is determined according to the content of each component described above. For example, diphenhydramine and / or One to 20000 parts by weight of γ-oryzanol can be mentioned per 100 parts by weight of the salt. From the viewpoint of more effectively improving the sebum secretion promoting action, γ-oryzanol is preferably 50 to 400 parts by weight, more preferably 150 to 250 parts by weight per 100 parts by weight of diphenhydramine and / or a salt thereof. It is done.
界面活性剤
また、本発明の皮脂分泌促進剤には、所望の製剤形態にするために、界面活性剤が含まれていてもよい。特に、γ−オリザノールが含まれる場合には、γ−オリザノールを可溶化又は乳化させて所望の製剤形態にするために、界面活性剤が含まれていることが好ましい。界面活性剤としては、薬学的に許容されることを限度として特に制限されず、ノニオン性界面活性剤、アニオン性界面活性剤、カチオン性界面活性剤、両性界面活性剤のいずれを使用してもよいが、好ましくはノニオン性界面活性剤が挙げられる。
Surfactant In addition, the sebum secretion promoter of the present invention may contain a surfactant in order to obtain a desired preparation form. In particular, when γ-oryzanol is contained, it is preferable that a surfactant is contained in order to solubilize or emulsify γ-oryzanol to obtain a desired preparation form. The surfactant is not particularly limited as long as it is pharmaceutically acceptable, and any of a nonionic surfactant, an anionic surfactant, a cationic surfactant, and an amphoteric surfactant can be used. A nonionic surfactant is preferably used.
界面活性剤としては、具体的には、ＰＯＥ（１０〜５０モル）フィトステロールエーテル、ＰＯＥ（１０〜５０モル）ジヒドロコレステロールエーテル、ＰＯＥ（１０〜５０モル）２−オクチルドデシルエーテル、ＰＯＥ（１０〜５０モル）デシルテトラデシルエーテル、ＰＯＥ（１０〜５０モル）オレイルエーテル、ＰＯＥ（２〜５０モル）セチルエーテル、ＰＯＥ（５〜５０モル）ベヘニルエーテル、ＰＯＥ（５〜３０モル）ポリオキシプロピレン（５〜３０モル）２−デシルテトラデシルエーテル、ＰＯＥ（１０〜５０モル）ポリオキシプロピレン（２〜３０モル）セチルエーテル等のポリオキシエチレンアルキルエーテル、これらのリン酸・リン酸塩（ＰＯＥセチルエーテルリン酸ナトリウムなど）、ＰＯＥ（２０〜６０モル）ソルビタンモノオレート、ＰＯＥ（１０〜６０モル）ソルビタンモノイソステアレート、ＰＯＥ（１０〜８０モル）グリセリルモノイソステアレート、ＰＯＥ（１０〜３０モル）グリセリルモノステアレート、ＰＯＥ（２０〜１００モル）・ポリオキシプロピレン変性シリコーン、ＰＯＥ・アルキル変性シリコーン、モノラウリン酸ポリエチレングリコール、モノパルミチン酸ポリエチレングリコール、モノステアリン酸ポリエチレングリコール、ジラウリン酸ポリエチレングリコール、ジパルミチン酸ポリエチレングリコール、ジステアリン酸ポリエチレングリコール、ジオレイン酸ポリエチレングリコール、ジリシノレイン酸ポリエチレングリコール、ポリオキシエチレン硬化ヒマシ油（５〜１００）、ポリソルベート（２０〜８５）、グリセリン脂肪酸エステル（モノステアリン酸グリセリン等）、水素添加大豆リン脂質、水素添加ラノリンアルコール等が挙げられる。これらの界面活性剤は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 Specific examples of the surfactant include POE (10-50 mol) phytosterol ether, POE (10-50 mol) dihydrocholesterol ether, POE (10-50 mol) 2-octyldodecyl ether, POE (10-50 mol). Mol) decyltetradecyl ether, POE (10-50 mol) oleyl ether, POE (2-50 mol) cetyl ether, POE (5-50 mol) behenyl ether, POE (5-30 mol) polyoxypropylene (5-5 mol) 30 mol) Polyoxyethylene alkyl ethers such as 2-decyltetradecyl ether, POE (10 to 50 mol) polyoxypropylene (2 to 30 mol) cetyl ether, phosphoric acid / phosphate thereof (POE cetyl ether phosphoric acid) Sodium), POE (20-60 mol) sol Tan monooleate, POE (10-60 mol) sorbitan monoisostearate, POE (10-80 mol) glyceryl monoisostearate, POE (10-30 mol) glyceryl monostearate, POE (20-100 mol) Polyoxypropylene modified silicone, POE / alkyl modified silicone, polyethylene glycol monolaurate, polyethylene glycol monopalmitate, polyethylene glycol monostearate, polyethylene glycol dilaurate, polyethylene glycol dipalmitate, polyethylene glycol distearate, polyethylene glycol dioleate, Polyglycol diricinoleate, polyoxyethylene hydrogenated castor oil (5-100), polysorbate (20-85), grease Phosphorus fatty acid ester (glyceryl monostearate etc.), hydrogenated soybean phospholipid, hydrogenated lanolin alcohol. These surfactants may be used individually by 1 type, and may be used in combination of 2 or more type.
本発明の皮脂分泌促進剤に、界面活性剤を含有させる場合、その含有量については、製剤形態等に応じて適宜設定すればよいが、例えば、０．１〜３０重量％が挙げられる。より具体的には、本発明の皮脂分泌促進剤がクリーム剤の場合であれば、界面活性剤の含有量として、０．１〜１５重量％、好ましくは０．５〜１０重量％が挙げられる。また、本発明の皮脂分泌促進剤が液剤の場合であれば、界面活性剤の含有量として、０．１〜３０重量％、好ましくは０．５〜１５重量％が挙げられる。 When the sebum secretion promoter of the present invention contains a surfactant, the content thereof may be appropriately set according to the formulation form and the like, for example, 0.1 to 30% by weight. More specifically, when the sebum secretion promoter of the present invention is a cream, the surfactant content is 0.1 to 15% by weight, preferably 0.5 to 10% by weight. . Moreover, when the sebum secretion promoter of this invention is a liquid agent, 0.1-30 weight% is mentioned as content of surfactant, Preferably 0.5-15 weight% is mentioned.
油性基剤
本発明の皮脂分泌促進剤は、所望の製剤形態への調製等のために、必要に応じて、油性基剤が含まれていてもよい。油性基剤としては、薬学的に許容されることを限度として特に制限されないが、例えば、植物油、動物油、鉱物油、脂肪酸アルキルエステル、脂肪酸、高級アルコール、シリコーンオイル等が挙げられる。
Oily Base The sebum secretion-promoting agent of the present invention may contain an oily base, if necessary, for preparation into a desired pharmaceutical form. The oily base is not particularly limited as long as it is pharmaceutically acceptable, and examples include vegetable oil, animal oil, mineral oil, fatty acid alkyl ester, fatty acid, higher alcohol, silicone oil and the like.
油性基剤として、具体的には、オリーブ油、小麦胚芽油、こめ油、サフラワー油、大豆油、つばき油、とうもろこし油、なたね油、ごま油、ひまし油、ひまわり油、綿実油、落花生油、ホホバ油、硬化油、アボガド油、ウイキョウ油、チョウジ油、ハッカ油、ユーカリ油、レモン油、オレンジ油、カルナウバロウ、キャンデリラロウ、コメヌカロウ、木ロウ等の植物油；ラード、魚油、スクワラン、蜜蝋等の動物油；パラフィン、水添ポリイソブテン、流動パラフィン、ゲル化炭化水素（プラスチベース等）、ワセリン等の鉱物油；アジピン酸ジイソプロピル、ミリスチン酸イソプロピル、パルミチン酸イソプロピル、パルミチン酸セチル、セバシン酸ジエチル、オレイン酸エチル等の炭素数４〜３０の脂肪酸と炭素数１〜３４のアルコールのエステル；ラウリン酸、ミリスチン酸、パルミチン酸、セバシン酸、オレイン酸、リノール酸等の炭素数４〜３０の脂肪酸；ミリスチルアルコール、セタノール、オレイルアルコール、ステアリルアルコール、イソステアリルアルコール、ベヘニルアルコール、ヘキサデシルアルコール、ラノリンアルコール等の炭素数６〜３４の１価高級アルコール；チルポリシロキサン、架橋型メチルポリシロキサン、環状シリコーン、アルキル変性シリコーン、アミノ変性シリコーン、ポリエーテル変性シリコーン、ポリグリセリン変性シリコーン、アクリルシリコーン、フェニル変性シリコーン等のシリコーンオイル等が挙げられる。これらの油性基剤は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 Examples of oily bases include olive oil, wheat germ oil, rice oil, safflower oil, soybean oil, camellia oil, corn oil, rapeseed oil, sesame oil, castor oil, sunflower oil, cottonseed oil, peanut oil, jojoba oil, hydrogenated Oil, avocado oil, fennel oil, clove oil, peppermint oil, eucalyptus oil, lemon oil, orange oil, carnauba wax, candelilla wax, rice bran wax, tree wax, etc .; animal oils such as lard, fish oil, squalane, beeswax; paraffin, Mineral oils such as hydrogenated polyisobutene, liquid paraffin, gelled hydrocarbon (plasty base, etc.), petrolatum, etc .; carbon number 4 such as diisopropyl adipate, isopropyl myristate, isopropyl palmitate, cetyl palmitate, diethyl sebacate, ethyl oleate ~ 30 fatty acids and C1-C34 alcohols Esters: fatty acids having 4 to 30 carbon atoms such as lauric acid, myristic acid, palmitic acid, sebacic acid, oleic acid, linoleic acid; myristyl alcohol, cetanol, oleyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, hexadecyl alcohol, Monohydric higher alcohols having 6 to 34 carbon atoms such as lanolin alcohol; chilled polysiloxane, cross-linked methylpolysiloxane, cyclic silicone, alkyl-modified silicone, amino-modified silicone, polyether-modified silicone, polyglycerin-modified silicone, acrylic silicone, phenyl Examples thereof include silicone oil such as modified silicone. These oily bases may be used alone or in combination of two or more.
本発明の皮脂分泌促進剤に、油性基剤を含有させる場合、その含有量については、製剤形態等に応じて適宜設定すればよいが、例えば、０．０５〜６０重量％が挙げられる。より具体的には、本発明の皮脂分泌促進剤がクリーム剤の場合であれば、油性基剤の含有量として、０．１〜６０重量％、好ましくは１〜４０重量％が挙げられる。また、本発明の皮脂分泌促進剤が液剤の場合であれば、油性基剤の含有量として、０．０５〜３０重量％、好ましくは０．１〜１５重量％が挙げられる。 When the oily base is contained in the sebum secretion promoter of the present invention, the content thereof may be appropriately set according to the formulation form and the like, for example, 0.05 to 60% by weight. More specifically, when the sebum secretion promoter of the present invention is a cream, the content of the oily base is 0.1 to 60% by weight, preferably 1 to 40% by weight. Moreover, when the sebum secretion promoter of this invention is a liquid agent, 0.05-30 weight% is mentioned as content of an oil-based base, Preferably 0.1-15 weight% is mentioned.
水
本発明の皮脂分泌促進剤は、所望の製剤形態への調製等のために、必要に応じて水が含まれていてもよい。
Sebum secretion promoters water present invention, for the preparation or the like into a desired dosage form, may contain water if necessary.
本発明の皮脂分泌促進剤に水を含有させる場合、その含有量については、製剤形態に応じて適宜設定すればよいが、例えば３０重量％以上、好ましくは４０〜９９．５重量％、更に好ましくは５０〜９９重量％、特に好ましくは６０〜９５重量％が挙げられる。 When water is contained in the sebum secretion promoter of the present invention, the content thereof may be appropriately set according to the preparation form, for example, 30% by weight or more, preferably 40 to 99.5% by weight, more preferably Is 50 to 99% by weight, particularly preferably 60 to 95% by weight.
その他の成分Other ingredients
本発明の皮脂分泌促進剤は、前述する成分の他に、必要に応じて、前述する成分以外の薬理成分を含有していてもよい。このような薬理成分としては、例えば、抗ヒスタミン剤（クロルフェニラミンマレイン酸塩等）、局所麻酔剤（プロカイン、テトラカイン、ブピパカイン、メピパカイン、クロロプロカイン、プロパラカイン、メプリルカイン又はこれらの塩、オルソカイン、オキセサゼイン、オキシポリエントキシデカン、ロートエキス、ペルカミンパーゼ、テシットデシチン等）、抗炎症剤（グリチルリチン酸ジカリウム、インドメタシン、フェルビナク、ジクロフェナクナトリウム、ロキソプロフェンナトリウム等）、皮膚保護剤（コロジオン、ヒマシ油等）、血行促進成分（ノニル酸ワニリルアミド、ニコチン酸ベンジルエステル、カプサイシン、トウガラシエキス等）、清涼化剤（メントール、カンフル等）、ムコ多糖類（コンドロイチン硫酸ナトリウム、グルコサミン等）等が挙げられる。これらの薬理成分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。これらの薬理成分を含有させる場合、その含有量については、使用する薬理成分の種類、期待する効果等に応じて適宜設定すればよい。 The sebum secretion promoter of the present invention may contain a pharmacological component other than the above-described components, if necessary, in addition to the above-described components. Such pharmacological components include, for example, antihistamines (chlorpheniramine maleate, etc.), local anesthetics (procaine, tetracaine, bupipacaine, mepipacaine, chloroprocaine, proparacaine, meprilucaine or salts thereof, orthocaine, oxesasein, oxy Polyentoxydecane, funnel extract, percamine ase, tesit decite, etc., anti-inflammatory agents (dipotassium glycyrrhizinate, indomethacin, felbinac, diclofenac sodium, loxoprofen sodium, etc.), skin protectants (colodione, castor oil, etc.), blood circulation promoting ingredients (nonyl acid) Vanillylamide, nicotinic acid benzyl ester, capsaicin, pepper extract, etc.), refreshing agent (menthol, camphor, etc.), mucopolysaccharide (chondroitin sulfate sodium Um, glucosamine, etc.) and the like. These pharmacological components may be used alone or in combination of two or more. When these pharmacological components are contained, the content may be appropriately set according to the type of pharmacological component to be used, the expected effect, and the like.
更に、本発明の皮脂分泌促進剤は、所望の製剤形態にするために、必要に応じて、前述する成分以外の基材や添加剤が含まれていてもよい。このような基剤や添加剤については、薬学的に許容されることを限度として特に制限されないが、例えば、多価アルコール（エチレングリコール、１，３−ブチレングリコール、プロピレングリコール、イソプレングリコール、ジエチレングリコール、ジプロピレングリコール、ポリプロピレングリコール、グリセリン等）、低級アルコール（エタノール、イソプロパノール等）、清涼化剤（メントール、カンフル、ボルネオール、ハッカ水、ハッカ油等）、防腐剤（メチルパラベン、プロピルパラベン、安息香酸、安息香酸ナトリウム、ソルビン酸等）、着香剤（シトラール、１，８−シオネール、シトロネラール、ファルネソール等）、着色剤（タール色素（褐色２０１号、青色２０１号、黄色４号、黄色４０３号等）、カカオ色素、クロロフィル、酸化アルミニウム等）、粘稠剤（ポリビニルピロリドン、アルギン酸ナトリウム、エチルセルロース、ヒドロキシプロピルメチルセルロース、カルボキシメチルセルロースナトリウム、キサンタンガム、カラギーナン等）、ｐＨ調整剤（リン酸、塩酸、クエン酸、クエン酸ナトリウム、コハク酸、酒石酸、水酸化ナトリウム、水酸化カリウム、トリエタノールアミン、トリイソプロパノールアミン等）、湿潤剤（ｄｌ−ピロリドンカルボン酸ナトリウム液、Ｄ−ソルビトール液、マクロゴール等）、安定化剤（ジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、エデト酸ナトリウム、メタリン酸ナトリウム、Ｌ−アルギニン、Ｌ−アスパラギン酸、ＤＬ−アラニン、グリシン、エリソルビン酸ナトリウム、没食子酸プロピル、亜硫酸ナトリウム、二酸化硫黄、クロロゲン酸、カテキン、ローズマリー抽出物等）、酸化防止剤、紫外線吸収剤、キレート剤、粘着剤、緩衝剤、溶解補助剤、可溶化剤、保存剤等の添加剤が挙げられる。これらの添加剤は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。これらの添加剤の含有量は、製剤形態等に応じて適宜設定することができる。 Furthermore, the sebum secretion promoter of the present invention may contain a base material and additives other than the components described above, if necessary, in order to obtain a desired pharmaceutical form. Such bases and additives are not particularly limited as long as they are pharmaceutically acceptable. For example, polyhydric alcohols (ethylene glycol, 1,3-butylene glycol, propylene glycol, isoprene glycol, diethylene glycol, Dipropylene glycol, polypropylene glycol, glycerin, etc.), lower alcohols (ethanol, isopropanol, etc.), refreshing agents (menthol, camphor, borneol, mint water, mint oil, etc.), preservatives (methylparaben, propylparaben, benzoic acid, benzoic acid) Acid sodium, sorbic acid, etc.), flavoring agents (citral, 1,8-shionale, citronellal, farnesol, etc.), coloring agents (tar pigments (brown 201, blue 201, yellow 4, yellow 403, etc.), Cocoa pigment, ku Lofil, aluminum oxide, etc.), thickeners (polyvinylpyrrolidone, sodium alginate, ethyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, xanthan gum, carrageenan, etc.), pH adjusters (phosphoric acid, hydrochloric acid, citric acid, sodium citrate, succinate) Acid, tartaric acid, sodium hydroxide, potassium hydroxide, triethanolamine, triisopropanolamine, etc.), wetting agent (sodium dl-pyrrolidonecarboxylate, D-sorbitol, macrogol, etc.), stabilizer (dibutylhydroxytoluene) Butylhydroxyanisole, sodium edetate, sodium metaphosphate, L-arginine, L-aspartic acid, DL-alanine, glycine, sodium erythorbate, gallic acid Pills, sodium sulfite, sulfur dioxide, chlorogenic acid, catechin, rosemary extract, etc.), antioxidants, UV absorbers, chelating agents, adhesives, buffers, solubilizers, solubilizers, preservatives, etc. Agents. These additives may be used individually by 1 type, and may be used in combination of 2 or more type. The content of these additives can be appropriately set according to the formulation form and the like.
製剤形態
本発明の皮脂分泌促進剤は、皮膚外用剤として使用されることが望ましい。本発明の皮脂分泌促進剤を皮膚外用剤として使用する場合、その形状については、経皮適用できることを限度として特に制限されないが、例えば、液状、固形状、半固形状（ジェル状、軟膏状、ペースト状）等が挙げられる。
Formulation Form The sebum secretion-promoting agent of the present invention is desirably used as a skin external preparation. When the sebum secretion promoter of the present invention is used as a skin external preparation, its shape is not particularly limited as long as it can be applied transdermally. For example, liquid, solid, semi-solid (gel, ointment, Paste) and the like.
また、本発明の皮脂分泌促進剤を皮膚外用剤として使用する場合、その製剤形態については、経皮適用できることを限度として特に制限されないが、例えば、皮膚外用医薬品、皮膚外用医薬部外品、化粧料、皮膚洗浄料等が挙げられる。本発明の皮脂分泌促進剤を皮膚外用剤にする場合の製剤形態として、具体的には、クリーム剤、ローション剤、ジェル剤、乳液剤、液剤、貼付剤、エアゾール剤、軟膏剤、パック剤等の皮膚外用医薬品；クリーム剤、ローション剤、ジェル剤、乳液剤、液剤、貼付剤、エアゾール剤、軟膏剤、パック剤等の皮膚外用医薬部外品；クリーム剤、ローション剤、ジェル剤、乳液剤、液剤、軟膏剤、パック剤等の化粧料；ボディーシャンプー、ヘアシャンプー、リンス等の皮膚洗浄料等が挙げられる。これらの製剤形態の中でも、好ましくは皮膚外用医薬品、更に好ましくはクリーム剤、ローション剤、ジェル剤、乳液剤、パック剤が挙げられる。 In addition, when the sebum secretion promoter of the present invention is used as a skin external preparation, the formulation form is not particularly limited as long as it can be applied transdermally. For example, skin external pharmaceuticals, skin external quasi drugs, cosmetics And skin cleansing materials. As a preparation form when the sebum secretion promoter of the present invention is used as an external preparation for skin, specifically, creams, lotions, gels, emulsions, solutions, patches, aerosols, ointments, packs, etc. Skin external medicines: creams, lotions, gels, emulsions, solutions, patches, aerosols, ointments, packs, etc .; external quasi-drugs such as creams, lotions, gels, emulsions And cosmetics such as liquids, ointments and packs; and skin cleansing agents such as body shampoos, hair shampoos and rinses. Among these preparation forms, preferably a skin external medicine, more preferably a cream, a lotion, a gel, an emulsion, or a pack.
用途・用量
本発明の皮脂分泌促進剤は、皮脂の分泌を促進することにより、皮膚の柔軟性、弾力性、バリア機能等を正常な状態に改善又は維持することができる。従って、本発明に皮脂分泌促進剤は、皮脂の分泌量が低下している皮膚の正常化、正常な皮膚における皮脂の分泌量の低下抑制等のために使用することができる。
Use / Dosage The sebum secretion-promoting agent of the present invention can improve or maintain skin flexibility, elasticity, barrier function, etc. in a normal state by promoting sebum secretion. Therefore, the sebum secretion-promoting agent according to the present invention can be used for normalization of the skin where the amount of sebum secretion is decreased, suppression of a decrease in the amount of sebum secretion in normal skin, and the like.
本発明の皮脂分泌促進剤は、皮脂の分泌量の低下が要因の一つになっている疾患や症状の予防又は治療にも有効である。皮脂の分泌量の低下が要因の一つになっている疾患や症状としては、具体的には、皮脂欠乏症、皮脂欠乏性皮膚炎、皮脂欠乏性湿疹、乾皮症、アトピー性皮膚炎、進行性指掌角皮症、足蹠角皮症、小児乾燥性湿疹、毛孔性苔癬、乾皮症、皮膚掻痒症、魚鱗癬、さめ肌、ひじ・ひざ・かかと・くるぶしの角化症、乾燥肌、手指のあれ、手足のひび・あかぎれ、小児乾燥性皮膚等が挙げられる。 The sebum secretion-promoting agent of the present invention is also effective for the prevention or treatment of diseases and symptoms in which a decrease in the amount of sebum secretion is a factor. Specific examples of diseases and symptoms caused by a decrease in the amount of sebum are sebum deficiency, sebum-deficient dermatitis, sebum-deficient eczema, xerosis, atopic dermatitis, progression Genital keratoderma, foot keratoderma, pediatric dry eczema, pore lichen, psoriasis, cutaneous pruritus, ichthyosis, shark skin, elbow, knee, heel, ankle keratosis, dry skin , Finger and finger / leg cracks / red skin, dry skin of children, and the like.
本発明の皮脂分泌促進剤の用量については、剤形、製剤形態、適用する症状の程度等に応じて適宜設定すればよい。例えば、本発明の皮脂分泌促進剤を皮膚外用剤として使用する場合であれば、その用量の一例として、１回当たり、皮膚１ｃｍ2当たり、ジフェンヒドラミン及び又はその塩が０．０１〜５０ｍｇ程度となる量で、１日１〜数回程度の頻度が挙げられる。 What is necessary is just to set suitably about the dosage of the sebum secretion promoter of this invention according to a dosage form, a formulation form, the grade of the symptom to apply, etc. For example, when the sebum secretion promoter of the present invention is used as an external preparation for skin, as an example of the dosage, diphenhydramine and / or a salt thereof is about 0.01 to 50 mg per 1 cm 2 of skin per one time. The amount may be about 1 to several times a day.
以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 EXAMPLES The present invention will be described more specifically with reference to the following examples, but the present invention is not limited to these examples.
試験例
表１に示す組成のクリーム剤（水中油型の乳化組成物）を調製した。クリーム剤の具体的な製造方法は、次の通りである。表１中の(I)に示す各成分を所定量混合して、８０℃に加温し、均一に撹拌することにより油相用組成物を調製した。また、別途、表１中の(II)に示す各成分を所定量混合して、８０℃に加温し、均一に撹拌することにより水相用組成物を調製した。得られた油相用組成物と水相用組成物を８０℃に加温した状態で混合して乳化処理を行った後に冷却し、クリーム剤を得た。
Test Example A cream (oil-in-water emulsion composition) having the composition shown in Table 1 was prepared. A specific method for producing the cream is as follows. A predetermined amount of each component shown in (I) of Table 1 was mixed, heated to 80 ° C., and stirred uniformly to prepare an oil phase composition. Separately, a predetermined amount of each component shown in (II) of Table 1 was mixed, heated to 80 ° C., and stirred uniformly to prepare an aqueous phase composition. The obtained oil phase composition and aqueous phase composition were mixed in a state heated to 80 ° C. and emulsified, and then cooled to obtain a cream.
得られたクリーム剤の皮脂分泌促進作用を評価した。具体的な試験方法は、次の通りである。ゴールデンハムスター（８週齢、雌）の耳介内部側に、クリーム剤を１日１回の頻度で塗布し、１５日目に耳介中央部の内部側の耳介皮膚片を医療用パンチで採取した。耳介皮膚片から外側の皮膚と軟骨を除去した後に、２Ｎの臭化ナトリウム水溶液に浸漬して表皮を剥離し、真皮シートを作成した。得られた真皮シートの皮脂腺をSudan IIIによって染色し、システム生物顕微鏡（オリンパス社製）にて皮脂腺を観察した。皮脂腺の面積を測定し、以下の算出式に従って、皮脂分泌量の相対値を算出した。 The sebum secretion promoting action of the obtained cream was evaluated. The specific test method is as follows. A cream is applied to the inside of the auricle of a golden hamster (8 weeks old, female) at a frequency of once a day. On the 15th day, the auricular skin piece inside the auricle central part is applied with a medical punch. Collected. After the outer skin and cartilage were removed from the auricular skin piece, the epidermis was peeled off by immersion in a 2N sodium bromide aqueous solution to prepare a dermis sheet. The sebaceous glands of the obtained dermis sheet were stained with Sudan III, and the sebaceous glands were observed with a system biological microscope (manufactured by Olympus). The area of sebaceous glands was measured, and the relative value of sebum secretion was calculated according to the following calculation formula.
本試験では、各群３匹のゴールデンハムスターを使用し、１匹から１枚の真皮シートを作成し、１枚の真皮シートにおいて、ランダムに選択した１５個の皮脂腺の面積を測定した。このようにして１群当たり合計４５個（Ｎ＝４５）の皮脂腺の面積を測定し、その平均値を各群の皮脂腺の面積として前記算出式に代入した。 In this test, three golden hamsters were used for each group, one dermis sheet was prepared from one animal, and the area of 15 randomly selected sebaceous glands was measured in one dermis sheet. In this way, the total area of 45 sebaceous glands per group (N = 45) was measured, and the average value was substituted as the area of sebaceous glands of each group into the calculation formula.
なお、本試験方法では、皮脂腺の大きさを測定することにより、皮脂分泌量を評価している。一般に、皮脂腺は全分泌腺であり、脂質を蓄積した細胞が自壊して皮脂となり、皮表に排出される。このため、皮脂腺の面積と皮脂腺機能には直接的な関係があり、皮脂分泌量と皮脂腺の面積は略比例関係にあることが一般的に知られている（小林美恵、皮脂腺に対するフェルラ酸エステル混合物の局所作用−生化学的および組織学的研究−、皮膚、第２１巻、第１号、公益社団法人日本皮膚科学会発行、昭和５４年２月）従って、本試験方法で得られた結果は、皮脂分泌量を正しく反映できている。 In this test method, the amount of sebum secretion is evaluated by measuring the size of the sebaceous glands. In general, sebaceous glands are total secretory glands, and lipid-accumulated cells self-destruct and become sebum, which is discharged to the skin surface. For this reason, there is a direct relationship between sebaceous gland area and sebaceous gland function, and it is generally known that sebum secretion and sebaceous gland area are approximately proportional (Mie Kobayashi, ferulic acid ester mixture for sebaceous gland) ), Skin, Vol. 21, No. 1, published by the Japanese Dermatological Association, February 1979) Therefore, the results obtained by this test method are It reflects the amount of sebum secretion correctly.
真皮シートをSudan IIIによって染色して顕微鏡観察した際の像を図１に示し、皮脂分泌量の相対値を求めた結果を表１に示す。この結果、ジフェンヒドラミンは単独でも、皮脂分泌促進作用があることが知られているγ−オリザノールよりも、高い皮脂分泌促進作用があることが確認された（実施例１）。また、ジフェンヒドラミンとヘパリン類似物質を併用した場合には、皮脂分泌促進作用がより一層向上しており（実施例２及び３）、特に、ジフェンヒドラミンとヘパリン類似物質とγ−オリザノールを併用した場合には、皮脂分泌促進作用が格段顕著に向上していた（実施例３）。 An image of the dermis sheet stained with Sudan III and observed under a microscope is shown in FIG. 1, and the results of determining the relative value of sebum secretion are shown in Table 1. As a result, it was confirmed that diphenhydramine alone has a higher sebum secretion promoting action than γ-oryzanol, which is known to have a sebum secretion promoting action (Example 1). In addition, when diphenhydramine and a heparin-like substance are used in combination, the sebum secretion promoting action is further improved (Examples 2 and 3). In particular, when diphenhydramine, a heparin-like substance and γ-oryzanol are used in combination. In addition, the sebum secretion promoting action was remarkably improved (Example 3).
処方例
表２に示すクリーム剤、表３に示すローション剤、表４に示すジェル剤、及び表５に示す乳液剤を調製した。これらの製剤は、いずれも、前記試験例の場合と同様に、皮脂の分泌を促進させる効果が期待され、皮脂分泌促進用途に有効である。
Formulation Example A cream shown in Table 2, a lotion shown in Table 3, a gel shown in Table 4, and an emulsion shown in Table 5 were prepared. Each of these preparations is expected to have an effect of promoting the secretion of sebum, as in the case of the above-mentioned test example, and is effective for the application of promoting sebum secretion.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017111634A JP2018203673A (en) | 2017-06-06 | 2017-06-06 | Sebum secretion promoter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017111634A JP2018203673A (en) | 2017-06-06 | 2017-06-06 | Sebum secretion promoter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2018203673A true JP2018203673A (en) | 2018-12-27 |
Family
ID=64956352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017111634A Pending JP2018203673A (en) | 2017-06-06 | 2017-06-06 | Sebum secretion promoter |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2018203673A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000143486A (en) * | 1998-11-12 | 2000-05-23 | Lion Corp | Skin preparation for external use |
| JP2000229884A (en) * | 1999-02-04 | 2000-08-22 | Lion Corp | Skin lotion |
| US20050238597A1 (en) * | 2004-04-26 | 2005-10-27 | Mccook John P | Topical treatment of acne, seborrheic dermatitis, and oily skin with formulations containing histamine antagonists |
| JP2010180206A (en) * | 2009-01-09 | 2010-08-19 | Rohto Pharmaceut Co Ltd | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2010184903A (en) * | 2009-02-13 | 2010-08-26 | Ikeda Mohando:Kk | External pharmaceutical composition |
| JP2016196419A (en) * | 2015-04-03 | 2016-11-24 | 万協製薬株式会社 | External preparation for skin |
-
2017
- 2017-06-06 JP JP2017111634A patent/JP2018203673A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000143486A (en) * | 1998-11-12 | 2000-05-23 | Lion Corp | Skin preparation for external use |
| JP2000229884A (en) * | 1999-02-04 | 2000-08-22 | Lion Corp | Skin lotion |
| US20050238597A1 (en) * | 2004-04-26 | 2005-10-27 | Mccook John P | Topical treatment of acne, seborrheic dermatitis, and oily skin with formulations containing histamine antagonists |
| JP2010180206A (en) * | 2009-01-09 | 2010-08-19 | Rohto Pharmaceut Co Ltd | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2015120766A (en) * | 2009-01-09 | 2015-07-02 | ロート製薬株式会社 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2016169240A (en) * | 2009-01-09 | 2016-09-23 | ロート製薬株式会社 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
| JP2010184903A (en) * | 2009-02-13 | 2010-08-26 | Ikeda Mohando:Kk | External pharmaceutical composition |
| JP2016196419A (en) * | 2015-04-03 | 2016-11-24 | 万協製薬株式会社 | External preparation for skin |
Non-Patent Citations (4)
| Title |
|---|
| "「主婦湿疹」とは？改善方法を解説", ココカラクラブ, JPN6022023403, 2016, ISSN: 0005067038 * |
| J. INVEST. DERMATOL., vol. 128, no. 5, JPN6021015058, 2008, pages 1280 - 1285, ISSN: 0005067037 * |
| ウレパールプラスローション10添付文書, JPN6021048522, 2012, ISSN: 0005067039 * |
| 池田重雄, 標準皮膚科学, vol. 第6版第3刷, JPN6022023401, 2002, pages 274, ISSN: 0005067036 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023086619A (en) | emulsion composition | |
| JP6666068B2 (en) | External composition | |
| JP5897164B2 (en) | Composition for external use | |
| JP2009184951A (en) | External skin care preparation composition | |
| WO2000009121A1 (en) | Anti-inflammatory analgesics | |
| CN108852865A (en) | A kind of fullerene topical composition | |
| TWI716394B (en) | External pharmaceutical composition | |
| JP7313111B2 (en) | Sebum secretion stimulator and composition for external use | |
| JP6725207B2 (en) | Skin pigmentation inhibitor | |
| JP6726498B2 (en) | External composition | |
| JP6495706B2 (en) | Skin external composition | |
| JP6920031B2 (en) | Chronic keratinized eczema improving agent | |
| JP2018203673A (en) | Sebum secretion promoter | |
| JP7361448B2 (en) | Transglutaminase expression promoter | |
| JP2018203672A (en) | Sebum secretion promoter | |
| JP5695310B2 (en) | External preparation composition containing γ-oryzanol | |
| JP6656890B2 (en) | Filaggrin production promoter | |
| JPH08109128A (en) | Preparation for treating allergic dermatopathy for external use | |
| JP6698318B2 (en) | Ceramide synthesis accelerator | |
| JP7153429B2 (en) | Active oxygen scavenging agent | |
| JP2019006697A (en) | Active oxygen scavenger | |
| JP6735587B2 (en) | External composition | |
| JP7329910B2 (en) | Skin topical composition | |
| JP7299682B2 (en) | Skin topical composition | |
| JP7025129B2 (en) | Muscle spasm remedy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200514 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210427 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210625 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210823 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220614 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221012 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230417 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230417 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230425 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230602 |